Expect to See Tirzepatide on Home Med Lists

July 2022

You’ll see patients coming in on the new injectable tirzepatide (Mounjaro)...the first “twincretin” for type 2 diabetes.

Think of it as similar to a glucagon-like peptide-1 (GLP-1) agonist...but it’s also a glucose-dependent insulinotropic polypeptide (GIP) agonist. More twincretins are in the works.

Both hormones are secreted in the gut in response to food...so the dual mechanism doesn’t seem to increase risk of hypoglycemia.

Get concise advice on drug therapy, plus unlimited access to CE

Hospital Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote